RaQualia Pharma Profit Margin

The latest profit margin for 4579.T is 4.13% as of June 2026. That compares with -16.27% in the prior-year period — up 125.4% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside RaQualia Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4579.T's profit margin moved from -16.27% to 4.13% — a 125.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RaQualia Pharma's valuation or profitability profile.

Against Healthcare companies, 4579.T currently prints 4.13% for profit margin, while the sector average sits near 9.48%. That is roughly 56.4% below the sector mean. Large gaps often invite a closer look at RaQualia Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively RaQualia Pharma converts resources into returns. At 4.13%, 4579.T may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -16.27% in the prior-year period — up 125.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4579.T's profit margin (4.13%), review year-over-year change from -16.27%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.